全文获取类型
收费全文 | 68535篇 |
免费 | 4995篇 |
国内免费 | 2319篇 |
专业分类
耳鼻咽喉 | 668篇 |
儿科学 | 1145篇 |
妇产科学 | 602篇 |
基础医学 | 9921篇 |
口腔科学 | 4869篇 |
临床医学 | 6645篇 |
内科学 | 7277篇 |
皮肤病学 | 789篇 |
神经病学 | 2148篇 |
特种医学 | 3838篇 |
外国民族医学 | 8篇 |
外科学 | 17371篇 |
综合类 | 8233篇 |
现状与发展 | 11篇 |
预防医学 | 2406篇 |
眼科学 | 611篇 |
药学 | 3842篇 |
22篇 | |
中国医学 | 1881篇 |
肿瘤学 | 3562篇 |
出版年
2024年 | 144篇 |
2023年 | 831篇 |
2022年 | 1591篇 |
2021年 | 2015篇 |
2020年 | 1934篇 |
2019年 | 1819篇 |
2018年 | 2109篇 |
2017年 | 1875篇 |
2016年 | 2179篇 |
2015年 | 2388篇 |
2014年 | 4185篇 |
2013年 | 5125篇 |
2012年 | 3600篇 |
2011年 | 4189篇 |
2010年 | 3390篇 |
2009年 | 3622篇 |
2008年 | 3694篇 |
2007年 | 3698篇 |
2006年 | 3416篇 |
2005年 | 3296篇 |
2004年 | 2787篇 |
2003年 | 2399篇 |
2002年 | 1774篇 |
2001年 | 1597篇 |
2000年 | 1426篇 |
1999年 | 1213篇 |
1998年 | 953篇 |
1997年 | 931篇 |
1996年 | 775篇 |
1995年 | 748篇 |
1994年 | 651篇 |
1993年 | 528篇 |
1992年 | 501篇 |
1991年 | 466篇 |
1990年 | 394篇 |
1989年 | 344篇 |
1988年 | 349篇 |
1987年 | 301篇 |
1986年 | 279篇 |
1985年 | 323篇 |
1984年 | 254篇 |
1983年 | 163篇 |
1982年 | 237篇 |
1981年 | 229篇 |
1980年 | 203篇 |
1979年 | 183篇 |
1978年 | 150篇 |
1977年 | 126篇 |
1976年 | 122篇 |
1973年 | 59篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
三维骨建模在全膝关节置换术中韧带平衡的作用 总被引:3,自引:3,他引:0
吴昊 《中国修复重建外科杂志》2006,20(6):607-610
目的探讨以三维骨建模为基础、无需影像的计算机辅助系统在人工全膝关节置换术(totalknee arthroplasty,TKA)中韧带平衡的作用。方法2002年11月~2003年6月,采用后稳定型人工全膝关节,在Ceravision无需影像资料的三维骨建模系统导航监控下,辅助完成TKA21例。男5例,女16例,年龄64~79岁,平均72.4岁。其中2例既往行胫骨近端截骨术,1例行股骨远端截骨术。14例膝内翻,7例膝外翻。术前下肢全长X线正位片测量,内翻13°~外翻13°,平均2.36°;膝关节X线正位片测量,应力下内翻平均8.47°(内翻2°~内翻20°),应力下外翻平均3.63°(内翻7°~外翻12°)。结果术中导航系统测量,额面内翻12°~外翻10°,平均3.33°,与术前比较差异有统计学意义(P<0.05);额面应力下内翻平均6.47°(内翻0°~内翻24°),应力下外翻平均4.32°(内翻8°~外翻15°),与术前比较差异有统计学意义(P<0.05)。术毕导航系统测得膝内外翻平均0.175°(内翻2°~外翻3°),而术后下肢全长X线正位片测量平均0.3°(内翻3.5°~外翻1.5°),二者差异无统计学意义(P>0.05)。术后3个月关节活动度为105~130°,平均115°,膝关节额面松弛度0.2~0.5cm,平均0.27cm。人工膝关节胫、股骨假体取得满意的对位置入和韧带平衡,无关节失稳和髌骨脱位等并发症发生。结论以三维骨建模为基础、无需影像的Ceravision系统,具有三维立体定位、优化截骨,并通过旋转对位和韧带松解获得伸屈膝关节等距间隙与韧带平衡稳定的作用,近期临床疗效满意,可在TKA中常规使用。 相似文献
12.
R. P. Heaney T. M. Zizic I. Fogelman W. P. Olszynski P. Geusens C. Kasibhatla N. Alsayed G. Isaia M. W. Davie C. H. Chesnut III 《Osteoporosis international》2002,13(6):501-505
Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy
in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined.
We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical
trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score =–3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n= 328) or placebo (n= 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up
to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4%
in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval
37% to 90%; P= 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were
stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of
70%, 95% CI 8% to 90%; P= 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P= 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women
with osteoporosis, with a similar magnitude of effect early and late after the menopause.
Received: 12 September 2001 / Accepted: 11 December 2001 相似文献
13.
Chronicsofttissuelesionisaspeciallymedicalterm,andanimportantpathologicalchangesofdiseases,suchaschronicoveruseinjuriesandconversionofacuteinjuriesinlowbackorfrominter-vertebraldiscprotrusion,anddislocationofintervertebraljointsaswell,whichmainlycauseseverepaininlowback犤1犦.Manypresentmethods(oralmedicine,massage,anestheticblock,physicalthera-piesetc.)havebeenusedforrelievingthepain,whichdemandsagreatfiscalsupportannually.Unfortunately,thereportsonthemechanismsandeffectofthem… 相似文献
14.
15.
T. M. Skerry M.D. M.R.C.V.S. R. Suswillo A. J. El Haj N. N. Ali R. A. Dodds L. E. Lanyon 《Calcified tissue international》1990,46(5):318-326
Summary Previous studies of Alcian blue-induced birefringence in adult avian cortical bone showed that a short period of intermittent
loading rapidly produces an increased level of orientation of proteoglycans within the bone tissue. In the absence of further
loading, this persists for over 24 hours. We have proposed that this phenomenon could provide a means for “capturing” the
effects of transient strains, and so provide a persistent, constantly updated strain-related influence on osteocyte populations
related to the bones' averaged recent strain history, in effect, a “strain memory” in bone tissue. In our present study, we
use the Alcian blue-induced birefringence technique to demonstrate that proteoglycan orientation also occurs after intermittent
loading of both cortical and cancellous mammalian bonein vivo andin vitro. We also show that the change in birefringence is proportional to the magnitude of the applied strain, and that the reorientation
occurs rapidly, reaching a maximal value after only 50 loading cycles. Examination of electron micrographs of bone tissue
after staining with cupromeronic blue allows direct visualization and quantification of the change in proteoglycan orientation
produced by loading. This shows that intermittent loading is associated with a realignment of the proteoglycan protein cores,
bringing them some 5 degrees closer to the direction of collagen fibrils in the bone matrix. 相似文献
16.
Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas 总被引:1,自引:0,他引:1
H. von Holst E. Knochenhauer H. Blomgren V. P. Collins L. Ehn M. Lindquist G. Norén C. Peterson 《Acta neurochirurgica》1990,104(1-2):13-16
Summary Eight patients with malignant gliomas verified on CT scan, received an intravenous injection of 50 mg of Adriamycin R, 24 hours prior to surgical removal of the tumour. Peroperatively, both tumour and surrounding tissue specimens were obtained for determination of the tissue concentrations of Adriamycin and its reduced metabolite Adriamycinol. It was found that Adriamycin could be detected in tumour tissue from all patients. The concentration varied between 0,9 and 4,6 nmol/g tissue. In contrast, Adriamycin could only be detected in surrounding brain tissue from one patient.In anin vitro study a human malignant glioma cell line (U-251 MG) was exposed to various concentrations of Adriamycin for 24 hours. It was found that an intracellular drug concentration above 30 nmol/g cells caused a concentration dependent inhibition of cell growth. Thus, it is likely that the poor effect of Adriamycin on patients with malignant gliomas is due to an ineffective drug accumulation in the tumour tissue. 相似文献
17.
A RELIABLE MARKER OF ENDOTHELIAL CELL DYSFUNCTION: DOES IT EXIST? 总被引:19,自引:0,他引:19
18.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献
19.
来源于骨髓和脐带血的基质细胞基本特性的比较 总被引:5,自引:0,他引:5
目的比较骨髓与脐带血细胞体外培养基质细胞的基本特性,为基质细胞的选择应用提供依据.方法用Dexter长期培养体系培养骨髓和脐带血基质细胞,以细胞增殖、细胞形态、细胞化学染色、细胞表面及基质细胞支持另一骨髓细胞形成的鹅卵石造血区(CAFC),长期培养起始细胞(LTC-IC)为指标,比较两者的生长特性、成分及功能.结果①细胞生长特性:出现贴壁细胞时间,骨髓细胞为培养3d,脐带血细胞为培养5~6d;细胞融合成片时间,骨髓细胞为培养10~14d,脐带血细胞为培养12~18d;第21天细胞增殖数,骨髓比脐带血细胞增殖少;②细胞成分:21d培养后细胞成分,骨髓来源者以成纤维细胞为主,其次是巨噬细胞与内皮细胞,脂肪细胞最少;脐带血细胞来源者,以巨噬细胞为主,其次是内皮细胞、成纤维细胞,偶见脂肪细胞;细胞化学与上述结果基本一致;细胞表面抗原检测,CD14、CD45的表达骨髓细胞明显低于脐带血细胞;③细胞功能:骨髓来源的基质细胞较脐带血细胞的基质细胞支持另一骨髓细胞形成的CAFC和LTC-IC明显多.结论①生长特征:形成贴壁细胞时间骨髓较脐带血短,骨髓细胞比脐带血细胞有核细胞数增殖快、持续时间相对短;②细胞成分特性:骨髓来源形成的基质细胞以成纤维细胞为主,脐带血来源者以巨噬细胞为主;③细胞功能特性:骨髓细胞形成的贴壁细胞较脐带血细胞形成的贴壁细胞更利于CAFC、LTC-IC生长. 相似文献
20.
窒息鼠脑组织型纤溶酶原激活物活性变化与脑水肿的关系 总被引:1,自引:1,他引:0
目的:探讨窒息对鼠脑分泌组织型纤溶酶原激活物(TPA)的影响与脑水肿的关系。方法:通过“延迟剖宫产术”致胎鼠宫内窘迫,实验分空白对照组,窒息15min组,窒息30min组,窒息15min复氧30min组,窒息30min复氧30min五个实验组,每组各取8例测试脑组织TAP的活性及含水量,结果:窒息后鼠脑TPA活性与含水量均升高(P<0.01),结论:窒息可致TAP活性增高,同时发生脑水肿,高活性的TPA可能是脑缺氧缺血致不可逆神经元损伤的一个重要媒介。 相似文献